CVS Health Raises Concerns about the Potential Impact of New Class of Cholesterol Drugs on the Health Care System

PCSK9 inhibitors could cost the health care system as much as $150 billion annually

Underscores urgent need for strategies to control cost while ensuring patient access

Feb 17, 2015, 09:00 ET from CVS Health